100 173

Cited 0 times in

Update on Familial Hypercholesterolemia: Diagnosis, Cardiovascular Risk, and Novel Therapeutics

DC FieldValueLanguage
dc.contributor.author이상학-
dc.date.accessioned2017-11-02T08:28:11Z-
dc.date.available2017-11-02T08:28:11Z-
dc.date.issued2017-
dc.identifier.issn2093-596X-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/154501-
dc.description.abstractIn recent studies, the reported prevalence of heterozygous familial hypercholesterolemia (FH) has been higher than in previous reports. Although cascade genetic screening is a good option for efficient identification of affected patients, diagnosis using only clinical criteria is more common in real clinical practice. Cardiovascular risk is much higher in FH patients due to longstanding low density lipoprotein cholesterol (LDL-C) burden and is also influenced by other risk factors. Although guidelines emphasize aggressive LDL-C reduction, the majority of patients cannot reach the LDL-C goal by conventional pharmacotherapy. Novel therapeutics such as proprotein convertase subtilisin/kexin type 9 inhibitors have shown strong lipid lowering efficacy and are expected to improve treatment results in FH patients.-
dc.description.statementOfResponsibilityopen-
dc.languageEnglish-
dc.publisherKorean Endocrine Society-
dc.relation.isPartOfEndocrinology and Metabolism (대한내분비학회지)-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/2.0/kr/-
dc.titleUpdate on Familial Hypercholesterolemia: Diagnosis, Cardiovascular Risk, and Novel Therapeutics-
dc.typeArticle-
dc.publisher.locationKorea-
dc.contributor.collegeCollege of Medicine-
dc.contributor.departmentDept. of Internal Medicine-
dc.contributor.googleauthorSang-Hak Lee-
dc.identifier.doi10.3803/EnM.2017.32.1.36-
dc.contributor.localIdA02833-
dc.relation.journalcodeJ00773-
dc.relation.journalsince2011~-
dc.identifier.pmid28116871-
dc.relation.journalbefore~2010 Journal of Korea Society of Endocrinology (대한내분비학회지)-
dc.subject.keywordCoronary disease-
dc.subject.keywordGenetics-
dc.subject.keywordHydroxymethylglutaryl-CoA reductase inhibitors-
dc.subject.keywordHyperlipoproteinemia type II-
dc.subject.keywordPCSK9 protein, human-
dc.contributor.alternativeNameLee, Snag Hak-
dc.contributor.affiliatedAuthorLee, Snag Hak-
dc.citation.titleEndocrinology and Metabolism (대한내분비학회지)-
dc.citation.volume32-
dc.citation.number1-
dc.citation.startPage36-
dc.citation.endPage40-
dc.identifier.bibliographicCitationEndocrinology and Metabolism (대한내분비학회지), Vol.32(1) : 36-40, 2017-
dc.date.modified2017-11-01-
dc.identifier.rimsid43073-
dc.type.rimsART-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.